The Oncology Institute (TOI)
(Delayed Data from NSDQ)
$4.28 USD
+0.12 (2.88%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $4.29 +0.01 (0.23%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TOI 4.28 +0.12(2.88%)
Will TOI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TOI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TOI
The Oncology Institute, Inc. (TOI) Reports Q2 Loss, Misses Revenue Estimates
TOI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for TOI
Three new option listings and one option delisting on July 24th
Oncology Institute (TOI) Receives Outperform Rating from Noble Capital | TOI Stock News
Oncology Institute initiated with bullish view at Noble Capital, here's why
Video: Friday Sector Laggards: Hospital & Medical Practitioners, Paper & Forest Products
Oncology Institute (TOI) Receives Positive Coverage with Buy Rating | TOI Stock News